Boston Scientific Announces Fourth Acquisition of the Year: Inks Deal to Acquire Intera Oncology, Developer of the FDA-Approved Intera 3000 Hepatic Artery Infusion Pump

Nov 26, 2024 18:12 CST Updated 18:12

Intera Oncology

Flow Pump Equipment Developer

Boston Scientific

Medical Device Manufacturer

November 25,Boston ScientificAnnounced agreement to acquire infusion pump manufacturer Intera Oncology, with the specific amount undisclosed. The transaction is expected to be completed in the first half of 2025.

It is reported that Intera Oncology has two core products.1. Hepatic artery infusion pump (Intera 3000); 2. Chemotherapy drug (floxuridine).Both have received FDA approval. The Intera 3000 can be used for hepatic artery infusion. (HAI) Treatment, mainly used for liver cancer caused by metastatic colorectal cancer.

Intera Oncology is an innovative medical device company headquartered in Boston, founded in 2019 by two doctors with a shared vision of improving survival rates for patients with colorectal cancer liver metastases and bile duct cancer by ensuring access to hepatic artery infusion therapy.

According to the press release,Intera 3000 remains the only FDA-approved constant-flow implantable pump for intrahepatic adjuvant therapy.

Boston Scientific stated that Intera is currently undergoing Phase II and Phase III studies to explore the use of this therapy in larger patient populations.

Peter Pattison, President of Boston Scientific's Intera Oncology and Embolization"Cancer is the leading cause of cancer-related deaths, and we are committed to providing meaningful solutions to safely and effectively treat various forms of liver cancer, minimizing systemic side effects and improving patient outcomes. Due to technological advancements, positive clinical results, and ongoing trials, there is growing interest in HAI therapy within the oncology community. We believe this acquisition will enable us to offer a more comprehensive set of solutions for doctors and their patients to treat both primary and metastatic cancers."

In recent years, Boston Scientific has been engaged in busy mergers and acquisitions:

In January 2024, Boston Scientific announced its agreement to acquire at a price of $71 per share, totaling$3.7 billionBoston Scientific Corporation Enters High-Growth Sacral Neuromodulation Market with Cash Acquisition of Axonics, a Manufacturer of Devices for Treating Urinary and Bowel Dysfunction.
In September, completed the acquisition of Silk Road Medical, gaining the world's first Transcarotid Artery Revascularization (TCAR) procedure, specifically designed to treat carotid artery blockages that may cause strokes;
In November, it was announced that the acquisition would be completed in the first half of 2025.Medical Technology Company for Atrial Fibrillation (AF) Diagnostic Mapping SolutionsCortex，Complement the electrophysiology product portfolio and provide solutions to advance the treatment of complex atrial fibrillation.

At the Investor Day event in September 2023, Boston Scientific emphasized that its focus on acquisitions is to strengthen its leadership position and accelerate its entry into faster-growing markets.

Earlier, at the end of 2022, Boston Scientific acquired a majority stake in Sinocare Medical, a domestic interventional treatment solutions company, valued atApproximately $523 million; In April 2023, in$615 millionAcquisition of Gastrointestinal Device Company Apollo Endosurgery. In 2021, it acquired Farapulse, thereby obtaining the world's first approved and marketed cardiac pulsed field ablation (PFA) product.

cr：https://www.massdevice.com/boston-scientific-to-acquire-hepatic-artery-infusion-pump-maker-intera-oncology/

?‍♂️

CIIE Heavyweight Review

Global Top 10 "Healthcare Black Tech" List

It's up to you to decide~

Press and hold the QR code below

EnterXiaohongshuParticipate in the list voting,

That means you have the opportunity to obtainMystery Prize~㊙

Swipe left or right to view more images

· END ·

--Featured Recommendations--

Boston Scientific Announces Fourth Acquisition of the Year: Inks Deal to Acquire Intera Oncology, Developer of the FDA-Approved Intera 3000 Hepatic Artery Infusion Pump

Intera Oncology

Boston Scientific

In recent years, Boston Scientific has been engaged in busy mergers and acquisitions:

In September, completed the acquisition of Silk Road Medical, gaining the world's first Transcarotid Artery Revascularization (TCAR) procedure, specifically designed to treat carotid artery blockages that may cause strokes;